Oculis Holding AG
OCS10.8701.36% ( -0.150 )
Oculis Holding AG (OCS)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Swit...
- Open
- 10.820
- High
- 11.390
- Low
- 10.750
- Prev. Close
- 11.020
- Volume
- 244.74K
- Turnover
- 2.67M
- Avg Price
- 10.903
- Bid/Ask Ratio
- --
- Amplitude
- 5.81%
- 52wk High
- 34.475
- Volume Ratio
- 1.12
- Turnover Ratio
- 0.49%
Oculis Holding AG Analyst Rating
View MoreForecast & Rating
Jul 6, 2026Price forecast
$37.95249.11%
Forecast & RatingStrong buy
11analysts
- Strong buy72.73%
- Buy27.27%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- cityam · Jul 21 at 11:07 PM
‘We are going to run out’: Mitie marks eleventh mega takeover of 2026
- Unusual Whales · Jul 2 at 03:01 AM
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
- StockTitan · Jul 1 at 07:00 PM
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference | OCS Stock News
- Tip Ranks · Jun 25 at 05:41 PM
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
- PUBT · Jun 19 at 01:57 AM
Oculis publishes optic neuritis privosegtor Phase 2 ACUITY OCT post-hoc analysis presentation
- PUBT · Jun 17 at 02:27 AM
Oculis shareholders approve capital band increase through May 2031
